Status:

COMPLETED

AFT/CLP-LAL RCT Stage 3 or 4 Pressure Injuries

Lead Sponsor:

Hill-Rom

Conditions:

Pressure Ulcer

Eligibility:

All Genders

18-85 years

Phase:

NA

Brief Summary

Patients who have at least one stage 3 or 4 PI and are admitted to a participating treating facility will be candidates for study enrollment. Patients must provide written informed consent. Standard c...

Detailed Description

Patients admitted to the LTACH with at least one stage 3 or 4 PI will be evaluated for possible inclusion/exclusion criteria. Patients will be approached by the investigator, or their designee to acqu...

Eligibility Criteria

Inclusion

  • Patient's treatment goals are curative or maintaining, and not palliative in nature.
  • Patient is compliant with standard clinical care for their admitted condition.
  • Patient's age is between 18 and 85 years
  • Patient is expected to have at least a 3-4-week length of stay (from date of assessment) in the treating LTACH
  • Patient must have at least one stage 3 or 4 PI located on the weight bearing aspect of the patient's truncal /pelvic region
  • Patients or their legal authorized representative must be willing and able to provide written informed consent.

Exclusion

  • Patient has an unstable spinal cord injury
  • Patient weighs less than 70 lbs or more than 350 lbs.
  • The primary study PI site has had previous flaps or grafts with significant associated scarring which is clinically thought to impede wound contracture.
  • Patients with PIs where bone exposure is \> 2 cm2 in area.
  • Patients with active osteomyelitis (via clinical assessment) or patients who have been diagnosed with osteomyelitis and have not yet completed a 6-8-week course of antibiotics
  • The primary study PI is located over the trochanteric head of the femur.
  • Patients that are currently taking or have taken in the last 6 weeks chemotherapy which is known to be cyto-toxic, or anti-angiogenic
  • Patients currently require immune modulating drugs (Humira (alalimumab), Orencia (abatacept), etc.)

Key Trial Info

Start Date :

May 10 2018

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 14 2019

Estimated Enrollment :

5 Patients enrolled

Trial Details

Trial ID

NCT03463434

Start Date

May 10 2018

End Date

August 14 2019

Last Update

August 15 2019

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Noland Health Anniston

Anniston, Alabama, United States, 36207

2

Noland Health

Birmingham, Alabama, United States, 35242